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PERANAN LIGAND RESEPTOR PEROKSISOM PROLIFERATOR-γ YANG 
DIAKTIFKAN (PPAR-γ) TERHADAP PEMBENTUKAN SEL BUSA 
DARIPADA MAKROFAJ YANG DIJANGKITI MNV-1 
 
ABSTRAK 
Aterosklerosis adalah penyakit kronik yang berpunca daripada pengumpulan 
sel busa daripada makrofaj di dalam lapisan intima pada arteri. Kajian yang telah 
dilakukan menunjukkan MNV­4 dapat mempercepatkan pembentukan aterosklerosis 
pada tikus. Memandangkan PPARγ kebanyakannya diekspresi di dalam makrofaj, 
manakala MNV­1 dapat menjangkiti makrofaj, kami membuat hipotesis bahawa 
PPARγ ligand (ciglitazone and 5d­PGJ2) boleh mengawalselia pembentukan 
aterosklerosis dengan mengawal pembentukan sel busa daripada makrofaj yang 
dijangkiti MNV­1. Kajian ini akan mendedahkan pengawalaturan PPARγ ligand 
pada pembentukan sel busa daripada sel makrofaj tikus (RAW264.7) yang dijangkiti 
MNV­1. Di dalam kajian ini, MNV­1 rekombinan dihasilkan melalui kaedah sistem 
genetik songsang dan hasilnya digunakan untuk merawat RAW264.7 bersama 
oxLDL dan PPARγ ligand. Selepas itu, sel­sel yang dijangkiti disahkan 
menggunakan tindakbalas rantai polimerase (PCR). Pembentukan sel busa dinilai 
dengan menggunakan pewarnaan minyak merah yang dianalisis menggunakan 
visualisasi mikroskopik dan kandungan kolesterol ester dalam RAW264.7 yang 
dirawat ditentukan dengan menggunakan kit pengukuran kolesterol ester Amplex 
Red. Aplikasi sistem genetik songsang berasaskan RNA berjaya menghasilkan 
MNV­1 yang berjangkit dengan hasil sebanyak 4.18 Log10TCID50/ml apabila 
diukur melalui titrasi menggunakan sel BV2. Keputusan kajian menunjukkan sampel 
xvi 
 
RAW+oxLDL+MNV+15d­PGJ2 merekodkan titer virus yang tertinggi diikuti 
dengan RAW+MNV+15d­PGJ2 pada 6, 12 and 24 jam. Manakala titer virus yang 
terendah direkodkan oleh sampel RAW+MNV+ciglitazone dan RAW+oxLDL+ 
MNV+ciglitazone. Pemerhatian mikroskopik pewarnaan minyak merah telah 
menunjukkan bahawa oxLDL boleh merangsang pembentukan sel busa dari masa ke 
masa dalam sel RAW264.7. Penambahan PPARγ ligand juga meningkatkan 
pengumpulan titisan lipid. Analisis menggunakan kaedah two­way ANOVA  
menunjukkan kesemua rawatan, jangka masa dan rawatan berbanding jangka masa 
mempunyai interaksi yang signifikan untuk semua rawatan. Perbandingan pada 24 
jam telah dipilih dan rawatan oxLDL pada sel RAW264.7 didapati meningkatkan 
kandungan kolesterol ester secara signifikan. Bagaimanapun penglibatan MNV­1 
tidak menunjukkan kenaikan kandungan kolesterol ester dalam semua sampel yang 
dirawat dengan oxLDL. Rawatan ciglitazone menunjukkan pengurangan kandungan 
kolesterol ester untuk semua rawatan kecuali sampel RAW+oxLDL+ciglitazone 
manakala 15d­PGJ2 tidak menunjukkan kesan yang ketara dalam pengurangan tahap 
kolesterol ester dalam semua rawatan. Kesimpulannya, berdasarkan kaedah 
pemulihan RNA virus yang digunakan dalam kajian ini berjaya menghasilkan MNV­
1 yang ditentukan genetiknya dan mampu berjangkit. oxLDL boleh merangsang sel 
busa dengan mendepositkan titisan lemak di dalam sitosol dan meningkatkan 
kandungan kolesterol ester. Jangkitan MNV­1 tidak menyebabkan pembentukan sel 
busa. Selain itu, 15d­PGJ2 dapat menggalakkan pembentukan sel busa. Akhir sekali, 
MNV­1 dan ciglitazone bekerja secara sinergi untuk merencatkan pembentukan sel 
busa. 
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ROLE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-γ 
(PPARγ) LIGANDS ON THE FOAM CELL FORMATION DERIVED FROM 
MNV-1 INFECTED MACROPHAGES 
 
ABSTRACT 
 Atherosclerosis is a chronic inflammatory disease initiated by the 
accumulation of macrophage­derived foam cells in the intima layer of artery. Murine 
norovirus­4 (MNV­4) has been shown to accelerate atherogenesis and increased 
macrophages content in atherosclerotic lesion in mice. Since PPARγ is predominatly 
expressed in macrophages whereby MNV­1 has a tropism for macrophages, we 
hypothesise that PPARγ ligands (ciglitazone and 15d­PGJ2) may regulate 
atherogenesis by controlling the formation of MNV­1­infected macrophages derived 
foam cells. In the current study, recombinant MNV­1 was produced using RNA 
based reverse genetics system and was used to treat the RAW264.7 cells with 
oxLDL, ciglitazone and 15d­PGJ2. Subsequently, infected cells were assayed for 
viral infection confirmation using polymerase chain reaction (PCR). Foam cells 
formation were assessed by microscopic visualisation of lipid droplets using Oil Red 
O (ORO) staining and measurement of Cholesterol Ester (CE) content in the treated 
RAW264.7 by using Amplex Red Cholesterol Ester measurement kit. The 
application of RNA based reverse genetic system had successfully generated 
infectious MNV­1 at yields of 4.18 Log10TCID50/ml dishes as measured by titration 
in BV2 cells. The result also showed that RAW+oxLDL+MNV+15d­PGJ2 sample 
produced the highest viral titres followed by RAW+MNV+15d­PGJ2. Meanwhile, 
the lowest virus titres recorded by RAW+MNV+ciglitazone and 
xviii 
 
RAW+oxLDL+MNV+ciglitazone. Microscopic visualisation of lipid droplets 
showed that oxLDL increased the accumulation of lipid droplets over the time in 
RAW264.7 cells. Addition of MNV­1, ciglitazone and 15d­PGJ2 in oxLDL­treated 
RAW264.7 cells also increased deposition of lipid droplets in the cytosol of treated 
cells. Two­way ANOVA has shown that the test for all treatment, time point and 
treatment versus time point had significant interaction. At 24 hours, we have found 
that oxLDL treatment in RAW264.7 cells in the presence of MNV­1, ciglitazone and 
15d­PGJ2 significantly increased CE contents. MNV­1 infection did not elicit CE 
content in oxLDL­treated RAW264.7 cells. In addition, 15d­PGJ2 but not ciglitazone 
increased CE content in oxLDL­treated RAW264.7 cells. MNV­1 and ciglitazone 
had synergistic effect in reducing CE content in oxLDL­treated RAW264.7 cells. In 
conclusion, RNA based virus recovery method used in the current study successfully 
produced genetically define infectious MNV­1. OxLDL stimulated foam cells 
formation by depositing lipid droplets in the cytosol areas and increased CE contents. 
MNV­1 infection may not trigger foam cells formation. On the other hand, 15d­PGJ2 
may promote foam cells formation. Finally, MNV­1 and ciglitazone work in synergy 
in inhibiting foam cells formation. 
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CHAPTER 1: LITERATURE REVIEW 
1.1 Atherosclerosis 
Atherosclerosis is defined as hardening and narrowing of the arteries due to 
accumulation of lipid laden foam cells and it can be considered as a lipid­mediated 
disease (Collot­Teixeira et al., 2007; Rader and Daugherty, 2008; Samson, Mundkur 
and Kakkar, 2012; Chung and Vafai, 2013; Annema, Eckardstein and Kovanen, 
2015). Aggregation of cholesterol­loaded macrophages in the arterial wall can cause 
chronic inflammatory disease that derives from an imbalance in lipid metabolism and 
a maladaptive immune response (Reiss et al., 2004; Moore, Sheedy and Fisher, 
2013). Atherosclerotic plaques tend to formed at the branch points of arteries which 
leads to disturbed or insufficient laminar flow to maintain the normal state of 
endothelium (Insull, 2009; Moore, Sheedy and Fisher, 2013). 
Atherosclerosis can lead to various cardiovascular diseases (CVD) such as 
myocardial infarction, stroke, coronary revascularization, angina pectoris, ischemic 
electrocardiographic changes, peripheral artery surgery, intermittent claudication 
(pain at rest), gangrene and loss of function (Moreno, 2003; Nagy et al., 2012; 
Frostegård, 2013; Pawlak, Mysliwiec and Pawlak, 2013; de Gaetano et al., 2015). 
According to World Health Organisation (WHO), CVD is a major cause of global 
mortality and estimated number of CVD cases will rise to 23.6 million by 2030 
(Samson, Mundkur and Kakkar, 2012). Furthermore, CEO of the National Heart 
Institute (IJN) has reported that there is a 5% increase in the number of cases IJN 
treats every year, with 10,000 cases of cardiology and hypertension and 4,000 cases 
of heart surgery. Previous study also has show that coronary artery disease (CAD) is 
one of the major cause of mortality and morbidity in Malaysia (Seong et al., 2016).  
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Arterial wall can increasing its external diameter to assist the plaque development 
without narrowing of the lumen in response to plaque growth thus explaining why 
atherosclerosis is asymptomatic until the last stage where the artery is totally clot and 
blocked (thrombosis) (Stocker and Keaney, 2004; Tedgui et al., 2006). Oxidised low 
density lipoprotein (oxLDL) and recruitment of leukocytes play a pivotal role in 
initiation of atherosclerosis development (Libby, Ridker and Maseri, 2002; Milioti et 
al., 2008; Samson, Mundkur and Kakkar, 2012; Pawlak, Mysliwiec and Pawlak, 
2013). Modifications of low­density lipoproteins (LDL) via oxidation process result 
in modification of their structure and function that can activate both innate and 
adaptive immune system (Nagy et al., 1998; Kearney, 2000; Chawla et al., 2001; 
Stocker and Keaney, 2004; Itabe, 2009). Atherosclerosis also can caused by other 
risk factors including hypertension, smoking, diabetes mellitus, genetic 
predisposition, and obesity (Willeit et al., 2000; Hadi, Carr and Al Suwaidi, 2005; 
Homem de Bittencourt et al., 2007; Insull, 2009; Azhar, 2010). Cigarette smoking 
and diabetes also can affect vascular biology but unfortunately, the mechanisms is 
less well understood (Libby, Ridker and Hansson, 2011).  
 
1.2 Lipoprotein 
Lipoproteins are particles that compose of hydrophobic core containing 
phospholipid, antioxidants, cholesterol ester, hydrophilic coat that contains free 
cholesterol (FC), vitamins, apolipoprotein molecules and phospholipid (Ginsberg, 
1998; Hegele, 2009). Insolubility of cholesterol and triglycerol in plasma restrict 
their movement from the liver to the bloodstream. Therefore, liver will undergo some 
modification by wrapping the lipid with certain protein namely apolipoprotein to 
form a new molecule called lipoprotein which act as a carrier protein and it also acts 
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as a transport vehicles for the lipid in the blood circulation (Ginsberg, 1998; Kumar 
et al., 2011). Most of the lipoprotein particles have a common structure in which they 
will form a  micellar complexes with a hydrophobic lipid core and an amphipathic 
surface monolayer (Ginsberg, 1998; Hegele, 2009; Kumar et al., 2011).  
The cholesterol and triglyceride are most important plasma lipids (Brown et al., 
1986; Hegele 2009). Cholesterol has numerous roles such as to trigger the activation 
of neuron signalling molecules, component of cell membranes, the precursor for 
steroid hormones, vitamin D, oxysterols and bile acids (Crockett, 1998; Hegele, 
2009). On the other hand, triglyceride synthesised in intestinal and liver cells, 
transported through the plasma and undergoes lipolysis in the endothelial cell surface 
(Brown et al., 1986; Hegele 2009). Triglycerides are mainly building up by FFSs and 
linked by ester bond to a glycerol backbone and it is play an important role in 
production of energy (Ginsberg, 1998; Hegele, 2009). 
 
1.2.1 Lipoprotein physiology 
Lipoprotein can be divided into different types such as chylomicron (CM), very low­
density lipoprotein (VLDL), low­density lipoprotein (LDL) and high­density 
lipoprotein (HDL). Each lipoprotein types (CM, VLDL, LDL and HDL) are 
distinguished based on their size, electrophoretic mobility, density, function and 
composition (Ginsberg, 1998; Hegele, 2009). Affinities of the apolipoproteins in the 
surface components of the lipoprotein will alter and it often diffuse from one 
lipoprotein and bind to another during lipoprotein metabolism (Itabe, 2009; Yoshida 
and Kisugi, 2010). Lipoprotein metabolism as shown in Figure 1.1 is a complex 
 network of assembly, 
2008; Hegele, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Lipoprotein metabolism
atherogenesis. It involves the transportation of lipids, particularly cholesterol and 
triglycerides, in the blood circulation. The intestine absorbs dietary fat and packages it 
into CM (large triglyceride
tissues through the blood. In muscle and adipose tissues, the enzyme lipoprotein lipase 
(LPL) breaks down CM, and fatty acids enter these tissues. The CM remnants are 
subsequently taken up by the liver. The liver loads lipids onto apoB and
VLDLs, which undergo lipolysis by LPL to form LDLs. LDLs are then taken up by the 
liver through binding to the LDL receptor (LDLR), as well as through other pathways. 
In contrast, HDLs are generated by the intestine and the liver through the secr
lipid­free apoA­I. ApoA
actions of the transporter ABCA1, forming nascent HDLs, and this protects apoA
from being rapidly degraded in the kidneys. In the peripheral tissues, nascent HDLs 
promote the efflux of cholesterol from tissues, including from macrophages, through 
the actions of ABCA1. Mature HDLs also promote this efflux by the actions of 
ABCG1. The free (unesterified) cholesterol in nascent HDLs is esterified to cholesteryl 
ester by the enzyme LCAT, creating mature HDLs. The cholesterol in HDLs is 
returned to the liver both directly, through uptake by the receptor SR
indirectly, by transfer to LDLs and VLDLs 
altered by the enzymes 
CETP and phospholipid transfer protein (PLTP), affecting HDL catabolism 
Daugherty, 2008). (Adapted from 
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1.2.2 Chylomicrons (CM) 
CM is lipoproteins that transports dietary lipids from the intestinal cells to another 
tissue (Ginsberg, 1998; Desvergne and Wahli, 1999; Zingg, Ricciarelli and Azzi, 
2000; Jain et al., 2007). Nascent CM is wrapped with a few types of apolipoprotein 
such as apoB­48, apoA­I, apoA­II and apoA­ IV (Ginsberg, 1998; Hegele, 2009). In 
the blood circulation, the nascent CM acquires apoE and apoC from plasma HDL in 
exchange for phospholipids (Ginsberg, 1998; Hegele, 2009). Triglycerols to be 
hydrolyzed into fatty acids when CM bind to membrane bound lipoprotein lipases 
(LPL) located in adipose and muscle tissues (Ginsberg, 1998; Lusis, Fogelman and 
Fonarow, 2004; Jain et al., 2007; Hegele, 2009). Fatty acids are resynthesised once 
again into triglycerols and stored once it is transported into the adipose cell while in 
the muscle, fatty acids are oxidised to provide energy (Desvergne and Wahli, 1999; 
Jain et al., 2007).  
 
1.2.3 Very Low Density Lipoproteins (VLDL) 
VLDL is synthesised in the liver and made up of fatty acids and cholesterol 
(Ginsberg, 1998; Lusis and Pajukanta, 2008). Liver secretes VLDLs via exocytosis 
and primary apolipoprotein of VLDL is apoB­100 (Ory, 2004; Hegele, 2009; Itabe, 
2009; Libby, Ridker and Hansson, 2011; Paik et al., 2015). Similar to CM, VLDL 
undergoes changes in the plasma in which the nascent VLDL acquires apoC and 
apoE from HDL (Ginsberg, 1998; Ory, 2004; Annema, Eckardstein and Kovanen, 
2015). Triglycerols are hydrolyzed into fatty acids when VLDL binds to the LPL in 
the adipose and muscle tissues (Ory, 2004; Hegele, 2009; Itabe, 2009). 
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In the muscle, fatty acids oxidation provides energy and transported into the adipose 
cell, then resynthesised once again into triglycerols and stored (Savage, 2005). 
Tissues absorb the fatty acids and monoglycerols, causing VLDL to shrink, formed 
IDLs and transfers its phospholipids and converts apoC to HDL (Ginsberg, 1998; 
Ory, 2004; Annema, Eckardstein and Kovanen, 2015). IDLs can be further 
catabolised by LPL in which they will lose apoE to form LDLs when it bind to liver 
cells receptors (Ginsberg, 1998; Annema, Eckardstein and Kovanen, 2015). 
 
1.2.4 Low Density Lipoproteins (LDL) 
LDL is a spherical cholesterol rich lipoprotein which contains mostly apoB­100 and 
play a critical role as a plasma cholesterol carrier in the blood (Mertens and Holvoet, 
2001; Colpo, 2005; Itabe, 2009; Kumar et al., 2011; Pawlak, Mysliwiec and Pawlak, 
2013). LDL content consists of cholesteryl esters that form hydrophobic core and 
triglycerides that are surrounded by phospholipid and cholesterol monolayer with a 
single molecule of apoB­100 as shown in Figure 1.2 (Mertens and Holvoet, 2001; 
Milioti et al., 2008; Kumar et al., 2011).  
In LDL surface’s phospholipids and FC are aligned, while triglycerides and 
cholesteryl ester are packed in the central core of the LDL particle (Milioti et al., 
2008; Itabe, 2009). LDL vary in both diameter (18–25 nm) and density (1.019–1.063 
g/ml) (Milioti et al., 2008; Kumar et al., 2011). LDL is known as bad cholesterol and 
it concentration positively correlates with the coronary heart disease (Ginsberg, 
1998; Samson, Mundkur and Kakkar, 2012; Annema, Eckardstein and Kovanen, 
2015). Oxidation of LDL is one of the early event in atherosclerosis since oxidized 
 LDL can contributes to atherogenesis 
Yoshida and Kisugi, 2010)
 
 
 
 
 
 
 
 
 
 
 
1.2.5 High Density Lipoprotein
HDL is secreted by live
when acquiring FC from cell membrane and triglycerol
(Eckardstein, Nofer and Assmann, 2001; Lusis and Paj
Daugherty, 2008). It always referred as good cholesterol because 
remove excess cholesterol 
metabolised into bile salts
Oram, 2003; Rader and Daugherty, 2008; Libby, Ridker and Hansson, 2011; 
Rosenson et al., 2012)
Figure 1.2: Schematic diagram of the low
as transporter of unesterified cholesterol, cholesterol ester, and triglycer
blood (Milioti et al. 2008). The size of LDL particle is approxiamately 21
composed of cholesterol ester a
contains of phospholipids and unesterified cholesterol in which a single protein called 
apoB­100 is embedded 
https://particulatefouling.wikispaces
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the liver since it contains Lechithin­cholesterol transferase (LCAT) enzymes that 
either esterify cholesterol or transfer cholesteryl esters (Eckardstein, Nofer and 
Assmann, 2001; Rader and Daugherty, 2008; Rosenson et al., 2012). LCAT 
catalyses the transfer of phospholipid’s long chain fatty acids to cholesterol and form 
cholesteryl ester (Eckardstein, Nofer and Assmann, 2001; Rader and Daugherty, 
2008; Rosenson et al., 2012). Exchanged process between cholesteryl esters and 
lipoproteins is mediated by cholesteryl ester transfer protein (CETP) that promotes 
transferring process of cholesterol esters from HDL to LDL, IDL and VLDL in 
exchange triglycerols and this process transforms VLDLs and IDLs into LDLs 
(Eckardstein, Nofer and Assmann, 2001; Ory, 2004; Jain et al., 2007; Rader and 
Daugherty, 2008). HDL will acquire apoE which increases their binding affinity 
towards receptors in the liver and absorbed and catabolised by the liver as it grow in 
size (Eckardstein, Nofer and Assmann, 2001; Ory, 2004; Jain et al., 2007). 
 
1.2.6 Oxidised Low Density Lipoprotein (oxLDL) 
In the subendothelial space, LDL will undergo oxidation process and become the 
main targets for the engagement of the LDL by scavenger receptor expressed by 
macrophages (Zingg, Ricciarelli and Azzi, 2000; Milioti et al., 2008; Yoshida and 
Kisugi, 2010; Ayyappan, Paul and Goo, 2016). OxLDL acts as chemoattractant 
substances for monocytes and stimulate inflammation in the arterial wall involving 
all of the atherogenesis phases (Itabe, 2009; Melo et al., 2011; Samson, Mundkur and 
Kakkar, 2012; Pawlak, Mysliwiec and Pawlak, 2013). OxLDL is composed of 
heterogeneous modified lipoprotein particles and cause difficulty in analyzing its 
structure (Itabe, 2009; Pawlak, Mysliwiec and Pawlak, 2013). Furthermore, oxLDL 
will not be degraded or processed for antigen presentation like other antigens but it 
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will internalize by the macrophage that will lead to the formation of the foam cell 
(Hansson, 2001). 
Commonly, LDL particle contains a single molecule of apoB as a major 
apolipoprotein, apoE, paraoxonase, and platelet­activating factor­acetylhydrolase 
(PAF­AH; also known as Lp­PLA2) (Mertens and Holvoet, 2001; Itabe, 2009; 
Kumar et al., 2011). Lipid molecules containing polyunsaturated fatty acids (PUFA) 
in LDL are easily oxidized under oxidative stress conditions and variety of lipid 
oxidation products is formed and this process subsequently covalently modified 
apoB protein as well (Itabe, 2009). Meanwhile, copper sulphate (CuSO4) treatment 
used to convert LDL into oxLDL in vitro (Itabe, 2009; Yoshida and Kisugi, 2010). 
 
1.3 Atherosclerosis development (atherogenesis) 
1.3.1 Structure of arterial wall 
Arterial wall can be divided into three layers and it composed of tunica intimal, 
tunica media, and adventitia layer (Lusis, 2000; Holzapfel et al., 2005; Shirai et al., 
2006; Libby, Ridker and Hansson, 2011; Chung and Vafai, 2013) (Figure 1.4a). 
Inner layer or tunica intima, is lined by EC monolayer and elastic fibres sheet, 
extracellular connective tissue matrix (proteoglycans and collagen) the internal 
elastic lamina, on the peripheral side that has a contact with blood overlying a 
basement membrane (Lusis, 2000; Libby, Ridker and Hansson, 2011). During 
atherogenesis, monocytes  will proliferate and migrate into the intima where they 
were further differentiated into macrophages and engulf the lipoproteins, forming 
foam cells (Smith et al., 1995; Newby and Zaltsman, 1999; Lusis, 2000; Milioti et 
al., 2008). The middle layer, or tunica media, contains mostly smooth muscle cells 
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(SMC) embedded in a complex extracellular matrix (Lusis, 2000; Libby, Ridker and 
Hansson, 2011; Frostegård, 2013). SMCs migrate from the media into the intima 
during atherogenesis, and proliferate in response to mediators such as platelet­ 
derived growth factor (Libby, Ridker and Hansson, 2011; Nagy et al., 2012). Outer 
layer of arteries called tunica adventitia, contains mast cells, fibroblasts, dendritic 
cells, monocytes/macrophages, T­cells, small vessels (also known as vasa vasorum 
that provide an important source of nutrition to arteries and veins), endothelial 
progenitor cells nerve endings and microvessels (Libby, Ridker and Hansson, 2011; 
Frostegård, 2013). Each layer of artery have a specific histological features and 
mechanical functions as shown in Figure 1.4a (Holzapfel et al., 2005; Libby, Ridker 
and Hansson, 2011). 
 
1.3.2 Fatty streaks formation 
In the normal condition LDL acts as a plasma cholesterol carrier in the blood but 
after undergo oxidization process, it will initiate the atherogenesis (Stocker and 
Keaney, 2004; Boullier et al., 2005; Corcoran et al., 2011; Kumar et al., 2011). As 
shown in Figure  1.4b, 1.4c and 1.4d, atherogenesis is initiated by lipid retention, 
oxidation, and modification that lead to the chronic inflammation, leading to 
formation and development of thrombosis or stenosis (Witztum and Steinberg, 1991; 
Chen et al., 1997; Koopman, Schaart and Hesselink, 2001; Stocker and Keaney, 
2004; Milioti et al., 2008; Insull, 2009; Itabe, 2009; Samson, Mundkur and Kakkar, 
2012). Normally, endothelium does not support binding of the white blood cells but 
during early initiation of an atherogenesis, oxLDL stimulates arterial EC to express 
selective adhesion molecules on their surface such as VCAM­1, ICAM­1 that bind to 
various receptor expressed on the leukocytes surface as shown in Figure 1.3 and 1.4b 
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(Lusis, 2000; Libby, Ridker and Maseri, 2002; Rader and Daugherty, 2008; Libby, 
Ridker and Hansson, 2011; Samson, Mundkur and Kakkar, 2012). In addition, 
monocyte chemoattractant protein­1 (MCP­1) is the main factor that is responsible to 
trigger the migration of monocytes into the intima (Van Lenten et al., 1995; Lusis, 
2000; Libby, Ridker and Maseri, 2002; Samson, Mundkur and Kakkar, 2012; 
Ayyappan, Paul and Goo, 2016). Inside the intima, macrophage colony­stimulating 
factor (M­CSF) is the growth factor that contributes to the differentiation of the 
blood monocyte into the macrophage as shown in Figure 1.3 and 1.4b (Smith et al., 
1995; Qiao et al., 1997; Libby, Ridker and Maseri, 2002; Rader and Daugherty, 
2008; Libby, Ridker and Hansson, 2011).  
In atherosclerotic arteries, macrophages involved transformed into foam cells 
through a process that regulated by the balance process between modified LDL 
uptake and cholesterol efflux (Ley, Miller and Hedrick, 2011; de Gaetano et al., 
2015). Formation of foam cells as shown in Figure 1.3 are comprising complex and 
multistep mechanisms that depend on different signalling pathways (Collot­Teixeira 
et al., 2007; Rader and Daugherty, 2008; Melo et al., 2011). 
Macrophages express scavenger receptors such as SRA­1 and CD36 that can 
recognise and internalise oxLDL (Mertens and Holvoet, 2001; Akiyama et al., 2002; 
Collot­Teixeira et al., 2007; Corcoran et al., 2011; Ley, Miller and Hedrick, 2011). 
The engagement of oxLDL by macrophages also will release various pro 
inflammatory mediators resulting in a chronic inflammatory reaction as shown in 
Figure 1.4b (Libby, Ridker and Hansson, 2011). Previous studies have showed 
various strong evidences that linked atherosclerosis with the immune response 
alteration and chronic inflammation (Insull, 2009; Kapoor et al., 2012; Samson, 
Mundkur and Kakkar, 2012; Matsuura et al., 2014). In order to maintain the 
 homeostasis, macrophages try to clean up cholesterol 
arteries (de Gaetano 
macrophages namely foam cells will form lipid streaks in the arteries which then 
trigger various inflammatory responses
Ricote et al., 1999; Ley, Miller and Hedrick, 2011; Libby, Ridker and Hansson, 
2011; Samson, Mundkur and Kakkar, 2012; de Gaetano 
can be considered as a precursor of advanced lesions
accumulation of lipid
Tedgui et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Recruitment of monocytes and formation of foam cells
blood enters the intima, where they are retained through binding to the extracellular 
matrix. LDLs are then modified by oxygen radicals, myelope
phospholipase A2 and sphingomyelinase. This results in the generation of pro
inflammatory biologically active lipids that initiate and maintain an active 
inflammatory process in the intima (not shown). This inflammation process will 
generate chemokines such as CX3CL1 and CCL2, which recruit monocytes to the 
intima. These monocytes then differentiate into macrophages under influence of MCF, 
which take up modified LDL through endocytosis or phagocytosis and become foam 
cells (lipid laden m
propagating the atherosclerotic plaque, including factors involved in lipid metabolism, 
inflammation and proteolysis 
Daugherty. 2008). 
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1.3.3 Formation of the fibrous cap (early fibro-atheroma or complex lesions) 
Fibrous cap formation can either progress to a complex atheroma or regress to a 
simpler plaque and its formation can remain asymptomatic (Tabas, 1997; Libby, 
Ridker and Maseri, 2002; Rader and Daugherty, 2008; Ellertsen, Petri and Bäck, 
2011; Frostegård, 2013). This stage initiated by the migration and proliferation of 
SMC into the intima or sub­endothelial space to produce a distinct fibrous cap 
(Newby and Zaltsman, 1999; Libby, Ridker and Maseri, 2002; Libby, Ridker and 
Hansson, 2011). Once the lesion reaches this stage, there are two possibilities; either 
the fibrous cap remains intact which stabilise the plaque, or plaque development 
continues and becomes more vulnerable and prone to rupture as shown in Figure 1.4c 
(Libby, Ridker and Maseri, 2002; Insull, 2009; Libby, Ridker and Hansson, 2011). 
 
1.3.4 Thrombosis 
Plaque erosions or rupture and thrombosis are depends on the composition and 
plaque weakness caused by chronic inflammatory condition that can be the most 
critical clinical aspect of atherosclerosis as shown in Figure 1.4d (Tabas, 1997; Lusis, 
2000; Collot­Teixeira et al., 2007; Libby, Ridker and Hansson, 2011). Thrombosis is 
the process that responsible for clinically observable events affecting peripheral 
vascular, coronary and cerebrovascular (Tedgui et al., 2006). Susceptibility to 
atherothrombosis differs not only in individual susceptibility but also in arterial 
susceptibility (Falk, 2006). 
 
 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4 Role of infectious agents in atherosclerosis 
There are several studies showed that the infection of bacteria and viruses are the 
factor that can contribute to the pathogenesis of atherosclerosis either directly by 
infection of vascular cells or indirectly by the immune system effects (Cainelli, 
Concia and Vento, 2000; Willeit et al., 2000; Prediman K. Shah, 2001; Madjid et al., 
2003; Reeves et al., 2004; Paik et al., 2011, 2015; Rosenfeld and Campbell, 2011; 
 
 
Figure 1.4: Stages in the development of atherosclerotic lesions. a) The normal 
artery contains three layers namely tunica adventitia, tunica media and tunica intima b) 
The atherogenesis initiated by the adhesion of blood leukocytes to the activated 
endothelial monolayer, facilitated the migration of the bound leukocytes into the intima, 
maturation of monocytes into macrophages, and their uptake of lipid which convert the 
lipid laden macrophages into foam cells. c) Lesion progression involves the migration 
of SMC from the media to the intima, the proliferation of SMC and the heightened 
synthesis of extracellular matrix macromolecules such as collagen, elastin and 
proteoglycans. Extracellular lipid derived from dead and dying cells can accumulate in 
the central region of a plaque, often denoted the lipid or necrotic core. d) Thrombosis, 
the ultimate complication of atherosclerosis, often complicates a physical disruption of 
the atherosclerotic plaque. The burst of the plaque’s fibrous cap will cause the blood 
coagulation components to come into contact with tissue factors in the plaque’s interior, 
triggering the thrombus to extend into the vessel lumen that can block blood circulation 
(Libby, Ridker and Hansson, 2011). (Adapted from Libby et al. 2011). 
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Dushkin, 2012; Tall and Yvan­charvet, 2015; Hsu et al., 2016). The findings were 
supported by in vivo studies that revealed an acceleration of the atherogenesis by 
infection (Reeves et al., 2004; Rosenfeld and Campbell, 2011; Dushkin, 2012; Paik 
et al., 2015). Infectious agent that has been reported as an accelerator for 
atherosclerosis are including C. pneumoniae, Porphyromonasgingi- valis (P. 
gingivalis), Helicobacter pylori (H. pylori), influenza A virus, hepatitis C virus 
(HCV), cytomegalovirus (CMV), murine norovirus (MNV) and human 
immunodeficiency virus (HIV) (Prediman K. Shah, 2001; Madjid et al., 2003; 
Reeves et al., 2004; Paik et al., 2011, 2015; Rosenfeld and Campbell, 2011; 
Dushkin, 2012; Tall and Yvan­charvet, 2015; Hsu et al., 2016). Infectious organisms 
have shown an ability to involve in the inflammation within the blood vessel either 
by directly infecting vascular cells or innate immune response activation (Rosenfeld 
and Campbell, 2011). Currently, there is a concept stated that not only one infectious 
agent is responsible for the atherogenesis but it caused by the aggregate effects of 
multiple infectious agents known as the ″infectious burden″ or ″pathogen burden″ 
(Prediman K. Shah, 2001; Rosenfeld and Campbell, 2011; Frostegård, 2013). 
Recently, murine norovirus­4 (MNV­4) infection has been shown to accelerate the 
atherosclerotic plaque development in mouse model of atherosclerosis (Paik et al., 
2011, 2015). The subsequent sections described about the MNV and their 
involvement in atherosclerosis development. 
 
1.5 Norovirus 
Norovirus that is earlier known as “Norwalk­like viruses” or “small round structured 
viruses,” is a non­enveloped viruses that have a positive­sense, linear and single­
stranded RNA genome from caliciviridae family (Green et al. 2001; Wobus et al. 
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2004; Waugh et al. 2014). Human noroviruses are one of the major factor of 
nonbacterial, epidemic gastroenteritis that typically lasting for 24 to 48 hours all over 
the world and most of the cases have been reported to occur in schools, nursing 
homes, hospitals, restaurants, and cruise ships (Hsu et al., 2005; Hwang et al., 2015; 
Paik et al., 2015). Norovirus infection caused gastroenteritis that develop symptom 
such as vomiting, diarrhea, low­grade fever, malaise, and abdominal cramping or 
pain (Wobus, Thackray and Virgin, 2006; Hsu, Riley and Livingston, 2007; 
Thackray et al., 2007; Kahan et al., 2011; Strong et al., 2012; Waugh et al., 2014; 
Niendorf et al., 2016).  It responsible for more than 90% of all epidemic nonbacterial 
gastroenteritis outbreaks (Subba­Reddy et al., 2012) and causing about 23 million 
infections per year in the United States alone (Thackray et al., 2007). Previously, 
MNV is the only norovirus that efficiently grows in tissue culture (Gonzalez­
Hernandez, Bragazzi Cunha and Wobus, 2012; Paik et al., 2015; Hsu et al., 2016). 
Due to inability of human norovirus to replicate in cell culture or small animal 
models, it has limited the research in order to have further understanding of the 
interaction between this virus and their hosts (Hardy, 2005; McFadden et al., 2011; 
Arias et al., 2012; Thorne, Bailey and Goodfellow, 2012; Waugh et al., 2014; Hwang 
et al., 2015).  
 
1.5.1 Murine norovirus (MNV) 
There are four types of MNV namely MNV­1, MNV­2, MNV­3, and MNV­4 
(Wobus, Thackray and Virgin, 2006). MNV­1 caused transient and short duration of 
infection while MNV­2, MNV­3 and MNV­4 can cause persistent and prolonged 
fecal shedding in infected immunocompetent mice infection (Wobus, Thackray and 
Virgin, 2006; Hsu, Riley and Livingston, 2007; Thackray et al., 2007). Genetically, 
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MNV is the most similar to HuNV and has been widely utilised as a surrogate to 
study norovirus in the cell culture system. Since first norovirus (MNV­1) was 
described in 2003, MNV model system has provides the first opportunity to 
understand the relationship between basic mechanisms and pathogenesis of norovirus 
in tissue culture and in the natural host (Wobus, Thackray and Virgin, 2006). The 
identification of the first MNV strain (MNV­1) propagation in the murine 
macrophage cell line RAW264.7 (Thackray et al., 2007) that originally isolated from 
the brain of severely immunocompromised mice by serial passage (Wobus, Thackray 
and Virgin, 2006). Discovery of the MNV­1 enables investigation of the molecular 
mechanisms that promote norovirus evolution and development of diagnostic assays 
(including immunohistochemistry) to detect viral antigens, serologic assays for 
detection of anti­MNV anti­ bodies, and molecular assays to detect viral RNA (Paik 
et al., 2015; Hsu et al., 2016). MNV is one of the virus from the Caliciviridae family 
that have single­stranded and positive­sense RNA where it infect mice and shown 
tropism toward antigen­presenting cells such as dendritic cells, macrophages and 
more recently, has been reported to infect B cells (Paik et al., 2015; Hsu et al., 2016).  
MNV genome consists of four open reading frames (ORFs) which are known as 
ORF1 that encodes a large polyprotein which is cleaved to produce the viral non­
structural proteins required for viral genome replication, (NS1­7); ORF2 that encodes 
the major capsid protein VP1; ORF3 that encodes a minor structural protein VP2 
whereas ORF4 encodes for virulence factor 1 (VF1) protein as shown in Figure 1.5 
(McFadden et al., 2011; Arias et al., 2012). 
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1.5.2 The association of MNV infection with atherogenesis 
In the previous study, MNV­4 infection has been shown to carry a potential in 
suppressing the ABCA1 transporter and increasing of CD36 expression (Paik et al., 
2015; Hsu et al., 2016). Possibility of infections in contributing to the development 
of atherosclerosis was suggested as early as 1800s and 1900s (Prediman K. Shah, 
2001). From the study that has been done by Paik et al, they have suggest that 
MNV4 infection may influences cellular cholesterol levels in macrophages by 
regulating uptake of oxLDL via CD36 and cholesterol efflux (ABCA1) pathways in 
bone marrow derived macrophages. Study that has been conducted also show that 
MNV infection did not influence glucose metabolism and weight gain, but it 
increased the size and macrophage content of aortic sinus lesions in Ldlr−/−mice fed 
an atherogenic diet. On the other hand, they also have suggest that MNV­4 infection 
have an effect to increases the oxLDL uptake capacity of macrophages since there is 
an increasing for CD36 protein expression (Paik et al., 2015).  While, study that has 
been conducted by Hsu et al. has reported that there are variable influence of MNV 
infection on the development of atherosclerosis (Hsu et al., 2016). 
 
Figure 1.5: Illustration of MNV genome organisation. Each protein coding region is 
illustrated as a single white box. ORF1 is translated into 7 different non­structural 
proteins (NS1/2 to NS7) that are released from precursor polyprotein after self­
proteolytic processing. ORF 2 encodes the major capsid protein VP1, ORF 3 encodes 
the minor capsid protein VP2, and ORF4 overlapping with ORF2 coding region encodes 
virulence factor VF1. Genomic and subgenomic RNAs contain a polyA tail at their 3' 
ends of variable length (Arias et al., 2012). (Modified from Arias et al. 2012). 
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1.6 Peroxisome Proliferator Activated Receptor (PPAR) 
Peroxisome proliferator activated receptors (PPAR) are transcription factors that is 
ligand­activated from a subfamily of the nuclear receptor gene family (Issemann and 
Green, 1990; Nagy et al., 1998; Azhar, 2010; Libby, Ridker and Hansson, 2011). 
PPARs exist in three sub­types namely PPARα, PPARδ/β, and PPARγ that is result 
from differential splicing (Brun et al. 1996; Ray et al. 2006; Tyagi et al. 2011; 
Norazmi et al. 2012). PPARα (NR1C1) is expressed in tissues with high fatty acid 
(FA) oxidation, such as heart, kidney, brown adipose tissue (BAT), and liver, where 
it regulates FA transport, esterification and oxidation via transcriptional activation of 
genes encoding enzymes involved in each step of FA breakdown. PPARγ (NR1C3) 
is predominantly express in adipose tissue and plays ban essential role in adipocyte 
differentiation and survival (Desvergne and Wahli, 1999; Evans et al., 2004; Metzger 
et al., 2005). While PPARβ/δ (NR1C2) is expressed ubiquitously but abundantly 
detected in skeletal muscle (Escher et al., 2001). 
 
1.6.1 Peroxisome Proliferator Activated Receptor (PPAR) structure 
All of the three PPAR isoforms (PPARα, PPARβ/δ, and PPARγ) have five or six 
structural regions within four functional domains that are A/B, C, D and E/F  as 
shown in Figure 1.6 (Nosjean and Boutin, 2002; Blanquart et al., 2003; Azhar, 2010; 
Wang, 2010; Grygiel­Górniak, 2014). N­terminal, A/B domain or ligand­
independent transactivation domain contains activation function (AF)­1 which is a 
target of phosphorylation process by kinases C domain of PPARs have a 70 amino 
acid­long PPAR DNA­binding domain consists of two highly conserved zinc finger 
motifs (Desvergne and Wahli, 1999; Guan and Breyer, 2001; Azhar, 2010). They 
stimulate the binding of receptor to a DNA sequence in the promoter region of target 
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genes known as the peroxisome proliferator response element (PPRE) (Zhang and 
Young, 2002; Argmann et al., 2003; Khoo et al., 2003; Grygiel­Górniak, 2014). The 
D domain or hinge region of PPAR acts as a base for cofactors binding (Auwerx, 
1999; Debril et al., 2001; Azhar, 2010). While, C­terminal, E/F domain or ligand­
binding domain (LBD) playing a main role for ligand specificity and activation of 
PPAR that lead to PPRE binding, thus increasing target genes expression (Desvergne 
and Wahli, 1999; Cunard et al., 2004; Azhar, 2010; Lefebvre, Benomar and Staels, 
2010). Ligand­dependent transactivation function 2 (AF­2) is responsible for 
recruitment of cofactors in order to assist the transactivation process (Desvergne and 
Wahli, 1999; Cunard et al., 2004; Azhar, 2010; Lefebvre, Benomar and Staels, 
2010).  
 
 
 
 
 
 
 
1.6.2 Peroxisome Proliferator Activated Receptor-γ (PPARγ) 
PPARγ is a transcription factor that plays a pivotal role in adipogenesis (Kubota et 
al., 1998; Auwerx, 1999; Debril et al., 2001; Guan and Breyer, 2001; Savage, 2005; 
Ray, Akbiyik and Phipps, 2006; Wang, 2010; Costa et al., 2010; Nagy et al., 2012; 
Takenaka et al., 2013; Grygiel­Górniak, 2014; Raman and Koenig, 2014; Annema, 
 
Figure 1.6: Schematic representation of the PPAR structure. PPAR proteins are 
organized in distinct domains which display specific function. The domain A/B contains 
the activating function 1 which is independent of the presence of ligand, the domain C is 
implicated in the DNA binding, the domain D is a hinge region and the domain E is 
implicated in the ligand recognition, contains an activating function 2 which is 
dependent of the presence of ligand and is necessary for the heterodimerization with 
RXR. Concerning the domain F, no function has been identified to date (Blanquart et 
al., 2003). (Modified from Blanquart et al. 2003). 
